DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
Trial Parameters
Brief Summary
This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent form * 18 years of age or older * Diagnosis of advanced or recurrent, histologically or cytologically confirmed metastatic or unresectable non-small cell lung cancer harboring NFE2L2 or KEAP1 alterations * Patients must have Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions * At the time of enrollment, patients must have experienced progression of disease following treatment with standard of care chemotherapy and immune checkpoint inhibitors either sequentially or concurrently * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Patient should consent to allow the acquisition of existing Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue, as unstained slides, if available or to undergo a fresh tissue biopsy to obtain fresh tumor tissue for performance of correlative studies if deemed feasible. Tumor biopsies should only be performed if deemed safe and feasible by the investigator. * Adequate basel